Overview Dividends

(CME) CME - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US12572Q1058

Futures, Options, Swaps, Clearing, Data

CME EPS (Earnings per Share)

EPS Growth (3Y CAGR): 12.89%
EPS Trend (3Y Correlation): 86.5%

CME Revenue

Revenue Growth (3Y CAGR): 9.18%
Revenue Trend (3Y Correlation): 85.8%

Description: CME CME September 25, 2025

CME Group Inc. (NASDAQ:CME) operates a global network of futures and options exchanges, offering contracts on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, metals, as well as fixed-income and currency trading services. Its business also includes clearing-house functions-settling, guaranteeing, and risk-mitigating futures, options, and cleared swaps-plus a suite of real-time and historical market-data products.

According to the 2023 annual report (the most recent publicly available filing), CME generated $5.5 billion in net revenue, with an average daily trading volume of roughly 30 million contracts and cleared-trade value exceeding $30 trillion. The firm holds an estimated 30 percent share of U.S. futures market volume, a position that is reinforced by its dominant role in interest-rate futures-a segment that typically expands when monetary-policy uncertainty rises.

The company’s client base spans professional traders, banks, asset managers, corporations, producers, and sovereign entities, including central banks. Its diversified product set makes it a bellwether for macro-economic shifts: for example, rising Treasury-yield volatility tends to boost demand for CME’s interest-rate futures, while commodity-price spikes drive higher activity in agricultural and energy contracts.

For a data-driven deep-dive into CME’s valuation metrics and scenario analyses, you might find the research tools on ValueRay worth exploring.

CME Stock Overview

Market Cap in USD	95,256m
Sub-Industry	Financial Exchanges & Data
IPO / Inception	2002-12-06

CME Stock Ratings

Growth Rating	84.8%
Fundamental	81.2%
Dividend Rating	76.6%
Return 12m vs S&P 500	11.7%
Analyst Rating	3.39 of 5

CME Dividends

Dividend Yield 12m	3.94%
Yield on Cost 5y	8.08%
Annual Growth 5y	15.22%
Payout Consistency	95.5%
Payout Ratio	87.1%

CME Growth Ratios

Growth Correlation 3m	-18.1%
Growth Correlation 12m	73.5%
Growth Correlation 5y	74.7%
CAGR 5y	21.63%
CAGR/Max DD 3y (Calmar Ratio)	1.86
CAGR/Mean DD 3y (Pain Ratio)	6.11
Sharpe Ratio 12m	2.15
Alpha	16.55
Beta	0.427
Volatility	17.33%
Current Volume	1847.4k
Average Volume 20d	1758.4k
Stop Loss	263.2 (-3%)
Signal	0.28

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (3.75b TTM) > 0 and > 6% of Revenue (6% = 383.8m TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA -0.96pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 50.23% (prev 38.40%; Δ 11.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.02 (>3.0%) and CFO 3.19b <= Net Income 3.75b (YES >=105%, WARN >=100%)

Net Debt (968.0m) to EBITDA (5.35b) ratio: 0.18 <= 3.0 (WARN <= 3.5)

Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (360.3m) change vs 12m ago 0.09% (target <= -2.0% for YES)

Gross Margin 86.14% (prev 86.06%; Δ 0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 3.94% (prev 4.39%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 29.45 (EBITDA TTM 5.35b / Interest Expense TTM 170.4m) >= 6 (WARN >= 3)

Altman Z'' 0.46

(A) 0.02 = (Total Current Assets 152.80b - Total Current Liabilities 149.59b) / Total Assets 187.14b

(B) 0.03 = Retained Earnings (Balance) 5.71b / Total Assets 187.14b

(D) 0.04 = Book Value of Equity 5.75b / Total Liabilities 158.95b

Total Rating: 0.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 81.16

1. Piotroski 3.50pt = -1.50

2. FCF Yield 3.26% = 1.63

3. FCF Margin 48.99% = 7.50

4. Debt/Equity 0.12 = 2.49

5. Debt/Ebitda 0.18 = 2.47

6. ROIC - WACC (= 5.33)% = 6.66

7. RoE 13.71% = 1.14

8. Rev. Trend 85.76% = 6.43

9. EPS Trend 86.53% = 4.33

What is the price of CME shares?

As of November 07, 2025, the stock is trading at USD 271.42 with a total of 1,847,436 shares traded.
Over the past week, the price has changed by +3.24%, over one month by +3.58%, over three months by -3.07% and over the past year by +28.19%.

Is CME a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, CME (NASDAQ:CME) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 81.16 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CME is around 298.97 USD . This means that CME is currently undervalued and has a potential upside of +10.15% (Margin of Safety).

Is CME a buy, sell or hold?

CME has received a consensus analysts rating of 3.39. Therefor, it is recommend to hold CME.

Strong Buy: 4
Buy: 3
Hold: 7
Sell: 4
Strong Sell: 0

What are the forecasts/targets for the CME price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	284.3	4.7%
Analysts Target Price	284.3	4.7%
ValueRay Target Price	329.9	21.6%

CME Fundamental Data Overview November 05, 2025

Market Cap USD = 95.26b (95.26b USD * 1.0 USD.USD)
P/E Trailing = 25.5721
P/E Forward = 22.779
P/S = 14.9183
P/B = 3.4484
P/EG = 5.589
Beta = 0.427
Revenue TTM = 6.40b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 2.68b USD (from longTermDebt, last fiscal year)
Short Term Debt = 749.8m USD (from shortTermDebt, last fiscal year)
Debt = 3.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 968.0m USD (from netDebt column, last quarter)
Enterprise Value = 96.10b USD (95.26b + Debt 3.42b - CCE 2.58b)
Interest Coverage Ratio = 29.45 (Ebit TTM 5.02b / Interest Expense TTM 170.4m)
FCF Yield = 3.26% (FCF TTM 3.13b / Enterprise Value 96.10b)
FCF Margin = 48.99% (FCF TTM 3.13b / Revenue TTM 6.40b)
Net Margin = 58.64% (Net Income TTM 3.75b / Revenue TTM 6.40b)
Gross Margin = 86.14% ((Revenue TTM 6.40b - Cost of Revenue TTM 886.7m) / Revenue TTM)
Gross Margin QoQ = 84.55% (prev 86.90%)
Tobins Q-Ratio = 0.51 (Enterprise Value 96.10b / Total Assets 187.14b)
Interest Expense / Debt = 1.29% (Interest Expense 44.0m / Debt 3.42b)
Taxrate = 22.85% (269.0m / 1.18b)
NOPAT = 3.87b (EBIT 5.02b * (1 - 22.85%))
Current Ratio = 1.02 (Total Current Assets 152.80b / Total Current Liabilities 149.59b)
Debt / Equity = 0.12 (Debt 3.42b / totalStockholderEquity, last quarter 28.19b)
Debt / EBITDA = 0.18 (Net Debt 968.0m / EBITDA 5.35b)
Debt / FCF = 0.31 (Net Debt 968.0m / FCF TTM 3.13b)
Total Stockholder Equity = 27.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.00% (Net Income 3.75b / Total Assets 187.14b)
RoE = 13.71% (Net Income TTM 3.75b / Total Stockholder Equity 27.36b)
RoCE = 16.71% (EBIT 5.02b / Capital Employed (Equity 27.36b + L.T.Debt 2.68b))
RoIC = 12.69% (NOPAT 3.87b / Invested Capital 30.51b)
WACC = 7.36% (E(95.26b)/V(98.68b) * Re(7.59%) + D(3.42b)/V(98.68b) * Rd(1.29%) * (1-Tc(0.23)))
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.09%
[DCF Debug] Terminal Value 80.02% ; FCFE base≈3.33b ; Y1≈3.78b ; Y5≈5.17b
Fair Price DCF = 248.1 (DCF Value 89.48b / Shares Outstanding 360.6m; 5y FCF grow 15.74% → 3.0% )
EPS Correlation: 86.53 | EPS CAGR: 12.89% | SUE: -0.91 | # QB: 0
Revenue Correlation: 85.76 | Revenue CAGR: 9.18% | SUE: 0.54 | # QB: 0

Additional Sources for CME Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle